Physician profile
Peter J Pappas
NPI 1801807748
$6,379.55
in general payments reported to CMS, 2019-2025
12 companies · $344 in 2025
The $344 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $236 · 2021: $577 · 2022: $169 · 2023: $2,458 · 2024: $2,400 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,500 · Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,500.00 |
| Food and Beverage | $1,701.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,817.22 | 2021-2025 | Venaseal, Abre, Closurefast |
| Boston Scientific Corporation | $573.69 | 2020-2023 | Varithena Administration Pack |
| Pfizer INC. | $250.12 | 2019-2025 | |
| Tactile Systems Technology INC | $167.19 | 2019-2024 | Entre Plus, Flexitouch Plus |
| Penumbra, INC. | $160.34 | 2025 | Ruby Coil |
| Biocompatibles, INC. | $148.51 | 2019 | |
| Nevro Corp. | $86.24 | 2023-2024 | Senza |
| Organogenesis INC. | $45.33 | 2021-2023 | Puraply |
| Janssen Pharmaceuticals, INC | $43.97 | 2020 | |
| Bard Peripheral Vascular, INC. | $42.34 | 2020 | |
| Cashflow Solutions, LLC | $30.15 | 2023 | Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White |
| E.R. Squibb & Sons, L.L.C. | $14.45 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Pappas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.